FILSPARI Data Show 75% IgAN Remission and Slower eGFR Decline in FSGS
TVTX has more than doubled off its 52-week low of $22.59.
Summary
Travere will present nine FILSPARI studies at ASN 2026, including SPARTAN data showing 75% complete proteinuria remission in IgAN and near-physiologic eGFR decline (-1.75 at week 110). DUPLEX FSGS analyses show greater proteinuria reduction (UPCR -48% vs -27% for irbesartan) and slower eGFR decline (-3.7 vs -6.2), with 20% vs 6% complete remission and 2% vs 8% kidney failure. These results strengthen FILSPARI's clinical differentiation in both indications and support broader uptake. The data follow Q2 2026 FILSPARI sales of $141.1M (up 96% YoY) and FDA approval for FSGS. Full peer-reviewed publication and updated treatment guidelines are the next potential catalysts.
At the time of this announcement, TVTX was trading at $56.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $22.59 to $68.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.